T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 937-943

  Weisdorf, Daniel ^a   Cooley, Sarah ^a   Devine, Steven ^b   Fehniger, Todd A ^c   DiPersio, John ^c   Anasetti, Claudio ^d   Waller, Edmund K ^e   Porter, David ^f   Farag, Sherif ^g   Drobyski, William ^h   Defor, Todd ^a   Haagenson, Michael ⁱ   Curtsinger, Julie ^a   Miller, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g INDIANA UNIVERSITY   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

Author keywords

Leukemia; Mismatch; Transplantation; Unrelated donor

Indexed keywords

FLUDARABINE; HLA C ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOIMMUNITY; ARTICLE; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; MULTICENTER STUDY; MYELOID LEUKEMIA; NATURAL KILLER CELL; PROSPECTIVE STUDY; RELAPSE; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION;

ADULT; ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID; LYMPHOCYTE DEPLETION; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RECEPTORS, KIR; T-LYMPHOCYTES; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 84862796459     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.024     Document Type: Article

References (31)

1. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
2. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
3. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
4. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
5. Davies S., Ruggeri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002, 100:3825-3827.
6. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006, 12:876-884.
7. Miller J.S., Cooley S., Parham P., et al. KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
8. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with Group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
9. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
10. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004, 103:1521-1526.
11. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
12. Beelen D.W., Ottinger H.D., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005, 105:2594-2600.
13. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
14. Karanes C., Nelson G.O., Chitphakdithai P., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:8-15.
15. MacMillan M.L., Davies S.M., Nelson G.O., et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:16-22.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
17. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
18. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:885-892.
19. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010, 28:3730-3738.
20. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
21. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004, 63:204-211.
22. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.
23. Di Ianni M., Falzetti F., Carotti A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
24. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004, 104:1923-1930.
25. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
26. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
27. Brunstein C., Wagner J.E., Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity. Blood 2009, 22:5628-5634.
28. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
29. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288. for the Blood and Marrow Transplant Clinical Trials Network.
30. Shilling H.G., McQueen K.L., Cheng N.W., Shizuru J.A., Negrin R.S., Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003, 101:3730-3740.
31. Stern M., de Angelis C., Urbani E., et al. Natural killer-cell KIR repertoire reconstitution after haploidentical SCT. Bone Marrow Transplant 2010, 45:1607-1610.